Mendelian randomization: Its impact on cardiovascular disease.

Area of Science:

• Genetics and Cardiovascular Medicine
• Human Genomics and Disease Etiology

Background:

• Cardiovascular diseases (CVD) share inheritable risk factors influenced by human genome variations.
• Single nucleotide polymorphisms (SNPs) contribute to individual genetic diversity and disease susceptibility.

Purpose of the Study:

• To explore the utility of Mendelian randomization studies (MRS) in elucidating causal relationships between biomarkers and cardiovascular disease (CVD).
• To assess the potential of MRS in predicting drug efficacy and guiding precision medicine for CVD prevention.

Main Methods:

• Utilizing genetic variants as proxies for biomarkers in a Mendelian randomization study (MRS) design.
• Analyzing both rare and common genetic variants with varying effect sizes to infer causality.
• Comparing outcomes between individuals with effect alleles and reference alleles.

Main Results:

• Mendelian randomization studies (MRS) demonstrate that lower low-density lipoprotein cholesterol (LDL-C) levels, driven by genetic variants, correlate with reduced coronary artery disease (CAD) risk.
• Genetic variants solely associated with higher high-density lipoprotein cholesterol (HDL-C) do not reduce myocardial infarction frequency, indicating HDL-C is a biomarker, not a direct cause.

Conclusions:

• Mendelian randomization studies (MRS) are valuable for establishing causality of risk factors in cardiovascular diseases.
• MRS can inform the development of targeted therapies and personalized prevention strategies for cardiovascular diseases, potentially becoming a standard preclinical process.